Mechanisms of action of topical budesonide and oral prednisolone in a rat model of chronic rhinosinusitis

Abstract

The inflammation and oxidase have emerged as two pivotal events in chronic rhinosinusitis (CRS) progression. Topical budesonide and oral prednisolone have been extensively used in the therapy of CRS. However, the difference of treatment effect of budesonide and prednisolone on CRS still unclear. This study found that inflammation level was upregulated in CRS rats compared with sham rats. Topical budesonide and oral prednisolone both suppressed the secretion of inflammation in serum of CRS rats, and there was no significant difference between two therapy approaches. Moreover, treatment with budesonide and prednisolone both attenuated the histopathological injury of nose mucous membranes of CRS rats. Furthermore, the expressions of anti-oxidation protein were detected by IHC, qRT-PCR and western blot, the results demonstrated that the expression of anti-oxidation proteins were upregulated in CRS rats compared with sham rats, and the treatment with budesonide and prednisolone both attenuated the expression of anti-oxidation proteins. Finally, we shown that budesonide and prednisolone inhibited the progression of CRS in rats by inhibiting TLR4/TRAF6/NF-κB signaling pathways. Collectively, these findings indicated that tipcal budesonide and oral prednisolone could inhibited the progression of CRS by blocking TLR4/TRAF6/NF-κB signaling pathways.